01—Abstract
Summary
Summary of the 10-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated reported product revenues, net of $363.7 milliona for the year ended December 31, 2024, up from $305.2 million in 2023, an increase of $58.5 million, or 19.2%, driven by ARIKAYCE sales growth in the US, Japan, and Europe and the rest of the world.
The company's only approved product is ARIKAYCE, which received accelerated approval in the US in 2018 and is subject to a confirmatory post-marketing trial (ENCORE) required for full approval. Net loss was $913.8 millionb in 2024 versus $749.6 million in 2023, and the accumulated deficit reached $4.4 billion. Operating expenses rose, with R&D up 4.8% to $598.4 million and SG&A up 33.9% to $461.1 million, reflecting commercial readiness activities for brensocatib.
The company's pipeline centers on brensocatib, a DPP1 inhibitor for bronchiectasis, whose NDA was accepted with priority review in February 2025 and carries a PDUFA target action date of August 12, 2025. Positive Phase 3 ASPEN topline results were announced in May 2024. Other programs include TPIP for PH-ILD and PAH and INS1201, an intrathecal gene therapy for DMD.
Cash and cash equivalents plus marketable securities totaled $1.43 billionc at year-end, and the company states this is sufficient to fund operations for at least the next 12 months. Total debt includes $574.9 million of 2028 Convertible Notes, $500.0 million of Term Loans at a 9.6% fixed rate, and a $150.0 million royalty financing arrangement. Investors should weigh the company's large and growing operating losses, reliance on ARIKAYCE revenue, concentration among three customers (85% of gross product revenue in 2024), and the regulatory dependence of both ARIKAYCE full approval and brensocatib launch timing.
02—Key points
Key Highlights
- Product revenues, net rose 19.2% to $363.7 million in 2024, led by US sales of $254.8 million and Japan sales of $87.7 million.
- Net loss widened to $913.8 million in 2024 from $749.6 million in 2023; accumulated deficit reached $4.4 billion.
- Brensocatib NDA for bronchiectasis accepted with priority review in February 2025, with an FDA target action date of August 12, 2025, and a planned US launch in Q3 2025 if approved.
- ARIKAYCE's US approval is accelerated; full approval depends on the ENCORE confirmatory trial (425 patients enrolled), with topline data anticipated in Q1 2026.
- Cash, cash equivalents and marketable securities totaled $1.43 billion at December 31, 2024, which the company says will fund operations for at least 12 months.
- Debt includes $574.9 million of 2028 Convertible Notes, $500.0 million of Term Loans at 9.6% fixed, and a $150.0 million OrbiMed royalty financing arrangement.
- Three largest customers accounted for 85% of gross product revenue in 2024, versus 88% in 2023.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 20, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $363.71M$305.21M | +19.2% |
| Cost of Revenue | $85.74M$65.57M | +30.8% |
| Gross Profit | $277.96M$239.63M | +16.0% |
| R&D Expenses | $598.37M$571.01M | +4.8% |
| SG&A Expenses | $461.12M$344.50M | +33.9% |
| Operating Expenses | $1.24B$1.01B | +22.4% |
| Operating Income | -$878.25M-$709.63M | −23.8% |
| Interest Expense | $84.91M$81.69M | +3.9% |
| Net Income | -$913.77M-$749.57M | −21.9% |
| EPS (Basic) | $-5.57$-5.34 | −4.3% |
| EPS (Diluted) | $-5.57$-5.34 | −4.3% |
| Shares Outstanding (Basic) | 164.04M140.43M | +16.8% |
| Shares Outstanding (Diluted) | 164.04M140.43M | +16.8% |
05—Questions
Frequently Asked Questions
What drove revenue growth in 2024?
Product revenues, net increased $58.5 million, or 19.2%, to $363.7 million, reflecting growth in ARIKAYCE sales in the US, Japan, and Europe and the rest of the world. US revenue grew 13.7%, Japan 33.4%, and Europe and rest of world 38.8%.
When could brensocatib be commercially available, and what is the approval timeline?
The FDA accepted the brensocatib NDA for bronchiectasis with priority review in February 2025 and set a PDUFA target action date of August 12, 2025. The company anticipates a US launch in the third quarter of 2025 if approved, with Europe and Japan launches expected in 2026.
Why is ARIKAYCE's full approval important?
ARIKAYCE received accelerated approval in the US, which requires a confirmatory trial. The company states that the ENCORE trial's clinical benefit verification is necessary for full approval, and a positive result may also support a label expansion to all MAC lung patients. Topline ENCORE data are expected in Q1 2026, and the company notes that the trial timetable agreed with the FDA has been delayed.
How much runway does the company have and what are its key obligations?
The company reported $555.0 million in cash and cash equivalents and $878.8 million in marketable securities at December 31, 2024, and states these will fund operations for at least the next 12 months. It also expects operating expenses and losses to continue, and it may raise additional capital. Debt obligations include the 2028 Convertible Notes maturing June 1, 2028, Term Loans maturing September 30, 2029 (subject to acceleration to February 1, 2028), and royalty payments to OrbiMed.
06—Continue